Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated September 24, 2021, titled "CAPLIN POINT S CRO AMARIS CLINICAL COMPLETES USFDA AUDIT WITH NIL OBSERVATIONS".
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated September 24, 2021, titled "CAPLIN POINT S CRO AMARIS CLINICAL COMPLETES USFDA AUDIT WITH NIL OBSERVATIONS".